Napo's late-stage proprietary gastro-intestinal compound, crofelemer,
is in various stages of clinical development for four distinct product
indications, including a late-stage Phase 3 program:
CRO-HIV for AIDS diarrhea, Phase 3
CRO-IBS for diarrhea irritable bowel syndrome ("D-IBS"), Phase 2
CRO-ID for acute infectious diarrhea (including cholera), Phase 2
CRO-PED for pediatric diarrhea, Phase 1
The FDA has granted fast-track status to CRO-IBS and CRO-HIV.
Crofelemer, a proprietary patented agent, is extracted from Croton lechleri, a medicinal plant which can be sustainably harvested from several countries in South America. Napo also plans to develop an early clinical stage product, NP-500, for the treatment of insulin resistant diseases of Type II diabetes and metabolic syndrome (Syndrome X; pre-diabetic syndrome). Napo also has a plant library of approximately 2,300 medicinal plants from tropical regions, and Napo has entered two screening relationship associated with this collection.
Currently, products are based on the chemical and biological diversity derived from plants with medicinal properties, but future products may be in-licensed from other sources.
Napo has partnerships with Glenmark Pharmaceuticals Limited of India and AsiaPharm Group Ltd. of China.
For more information please visit http://www.napopharma.com.
ISPOR promotes the science of pharmacoeconomics (health economics) and outcomes research (the scientific discipline that evaluates the effect of health care interventions on patient well-being including clinical outcomes, economic outcomes, and patient-reported outcomes) and facilitates the translation of this research into useful information for healthcare decision-makers to ensure that society allocates scarce health care resources wisely, fairly and efficiently.
|SOURCE Napo Pharmaceuticals, Inc.|
Copyright©2008 PR Newswire.
All rights reserved